<ul>
<li>Immunic appointed Michael W. Bonney as chair of the board, effective May 16, 2026.     *      Simona Skerjanec moved from interim chair to remain a board member.     *      Bonney previously held senior commercial leadership roles at Biogen, where he worked on the launch and growth of Avonex for multiple sclerosis.     *      He later served as CEO of Cubist Pharmaceuticals for more than 10 years, leading commercialization of Cubicin and the company’s sale to Merck for about USD 9.5 billion. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2329356_en), on May 19, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</li>
</ul>

IMUX

BIIB

<p>Immunic has appointed Michael W. Bonney as chair of the board, effective May 16, 2026, replacing interim chair Simona Skerjanec, who will remain a board member. Bonney has a strong background in the pharmaceutical industry, having previously held senior roles at Biogen and served as CEO of Cubist Pharmaceuticals, leading its sale to Merck for approximately USD 9.5 billion.</p>

PUBT

Immunic

Merck

Biogen

iShares Global Healthcare

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

iShares US Pharma

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

Health Care Select Sector SPDR

Invesco Nasdaq Biotechnology ETF

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

Ark Genomic Revolution ETF

VG Health

Immunic names Michael Bonney board chair, replacing interim chair Simona Skerjanec